Tarsus Q2 2024: XDEMVY net sales $40.8M (65% QoQ), net loss $33.3M, gross-to-net improves to 44%

Tarsus Pharmaceuticals, Inc.

2024-Q2 EPS reported -$1.89 revenue$68,427,000

XDEMVY net product sales $40.8M in Q2, up 65% over Q1; year-to-date $65.5M.
Gross-to-net discount improved to 44% from 55% in Q1; steady state expected low 40% in 2025.
More than 37,000 bottles delivered to patients in Q2; ~11,000 ECPs have started patients launch-to-date.
Net loss $33.3M (($0.88) per share) vs $31.4M in Q2 2023; SG&A $58.8M vs $20.3M due to launch costs.
Cash $323.6M including ~$39.6M from new credit facility draw; sales force expansion to ~50 additional reps by end of Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.